Abstract
Heart failure remains the main cause of death in children with heart disease. In USA and Europe hospital mortality of children with heart failure is about 7% of children, nearly twice as high as in adults. In this review a group of authors report about their experience with beta-blockers in childhood heart failure. Most of them start to treat children with severe heart failure at a time - 20 years ago - when beta blockers seem to be contraindicated in this situation. The physicians and their patients and/or parents all are aware of the risk of this decision. However, unproven medical therapies for heart failure are the most important therapeutical dilemma in pediatric cardiology. The authors carefully observed a highly selected group of patients with the highest risk to die and had the patience to wait for the longtime follow up. Today - based upon this experience –we know that beta blockers are safe and may save the lives of many children with heart disease all over the world. Together with young colleagues who enthusiastically support this idea the authors now intend to break down the “wall of ignorance” for this promising therapy in pediatric cardiology.
Keywords: Beta-blockers, childhood, duchenne, heart failure, hypertrophic cardiomyopathy, sudden death.
Reviews on Recent Clinical Trials
Title:Editorial (Thematic Issue: The Long Way to a Successful Medical Therapy of Heart Failure with Beta-blockers in Children with Heart Disease)
Volume: 9 Issue: 2
Author(s): Reiner Buchhorn and Robert D. Ross
Affiliation:
Keywords: Beta-blockers, childhood, duchenne, heart failure, hypertrophic cardiomyopathy, sudden death.
Abstract: Heart failure remains the main cause of death in children with heart disease. In USA and Europe hospital mortality of children with heart failure is about 7% of children, nearly twice as high as in adults. In this review a group of authors report about their experience with beta-blockers in childhood heart failure. Most of them start to treat children with severe heart failure at a time - 20 years ago - when beta blockers seem to be contraindicated in this situation. The physicians and their patients and/or parents all are aware of the risk of this decision. However, unproven medical therapies for heart failure are the most important therapeutical dilemma in pediatric cardiology. The authors carefully observed a highly selected group of patients with the highest risk to die and had the patience to wait for the longtime follow up. Today - based upon this experience –we know that beta blockers are safe and may save the lives of many children with heart disease all over the world. Together with young colleagues who enthusiastically support this idea the authors now intend to break down the “wall of ignorance” for this promising therapy in pediatric cardiology.
Export Options
About this article
Cite this article as:
Buchhorn Reiner and Ross D. Robert, Editorial (Thematic Issue: The Long Way to a Successful Medical Therapy of Heart Failure with Beta-blockers in Children with Heart Disease), Reviews on Recent Clinical Trials 2014; 9 (2) . https://dx.doi.org/10.2174/157488710902141009103818
DOI https://dx.doi.org/10.2174/157488710902141009103818 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antioxidants in Peripheral Arterial Disease
Current Drug Targets Reviewing the Cardiovascular Complications of HIV Infection After the Introduction of Highly Active Antiretroviral Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Surgical Ventricular Restoration to Reverse Left Ventricular Remodeling
Current Cardiology Reviews Aptamers in Drug Design: An Emerging Weapon to Fight a Losing Battle
Current Drug Targets Update on the Pathophysiological Role of Intracellular Signaling Pathways in Atherosclerotic Plaques and Ischemic Myocardium
Current Signal Transduction Therapy Editorial [ Reducing Cardiovascular Risk: Is Low-Density Lipoprotein-Cholesterol (LDL-C) Lowering Enough? ]
Current Vascular Pharmacology Antiplatelet and Anticoagulation Therapy in Structural Heart Disease Interventions Beyond TAVI
Current Pharmaceutical Design Optimized Model for Cervical Cancer Detection Using Binary Cuckoo Search
Recent Patents on Computer Science Mycobacterial DNA GyrB Inhibitors: Ligand Based Pharmacophore Modelling and In Vitro Enzyme Inhibition Studies
Current Topics in Medicinal Chemistry Hypertension and Diabetes: Emphasis on the Renin – Angiotensin System and Insulin Resistance
Current Hypertension Reviews Drugs for the Treatment of Hypercholesterolemia and their Benefits Beyond Cholesterol Lowering to Prevent Vascular Disease
Vascular Disease Prevention (Discontinued) From 2D to 3D - a New Dimension for Modelling the Effect of Natural Products on Human Tissue
Current Pharmaceutical Design Role of Heme Oxygenase-1 in Cardiovascular Function
Current Pharmaceutical Design Ex Vivo and In Vivo Approaches to Study Mechanisms of Cardioprotection Targeting Ischemia/Reperfusion (I/R) Injury: Useful Techniques for Cardiovascular Drug Discovery
Current Drug Discovery Technologies A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes
Current Pharmaceutical Design An Overview of Non-Neural Sources of Calcitonin Gene-Related Peptide
Current Medicinal Chemistry Synthetic Sustained Gene Delivery Systems
Current Topics in Medicinal Chemistry Strategies for Effective Naked-DNA Vaccination Against Infectious Diseases
Recent Patents on Anti-Infective Drug Discovery The Problem of Atrial Fibrillation in Patients with Chronic Kidney Disease
Current Vascular Pharmacology Why Multiples of 21? Why does Selenoprotein P Contain Multiple Selenocysteine Residues?
Current Nutraceuticals